Stocks · News reference

Capricor Therapeutics Announces 24-Month HOPE-3 Data On Deramiocel In Duchenne Muscular Dystrophy To Be Presented At World Muscle Society Congress September 29 To October 3

Sep 17, 2026, 12:31 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 17, 2026, 12:31 PM
Checked: Sep 17, 2026, 12:31 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 5, 2026, 6:12 PMBenzinga Newsdesk
Capricor Therapeutics shares are trading lower after the company announced extension data from its ongoing HOPE-3 OLE study of Deramiocel on upper limb in Duchenne muscular dystrophy, which included 12-month and 24-month observations.
CAPR
BenzingaOct 5, 2026, 5:59 PMVandana Singh
What's Going On With Capricor Therapeutics Stock Monday?
Capricor Therapeutics (CAPR) shares top-line HOPE-3 extension data for Deramiocel in DMD ahead of its Nov 22 FDA PDUFA date.
CAPR
BenzingaOct 5, 2026, 1:07 PMBenzinga Newsdesk
Capricor Therapeutics Presents New Data From Ongoing HOPE-3 OLE Study For Its Lead Asset, Deramiocel, For Treatment Of Upper Limb Impairment In DMD, At 31st Annual Congress Of WMS In Hiroshima
CAPR
BenzingaSep 30, 2026, 3:18 PMHenry Khederian
Capricor Therapeutics Stock Surges: What's Going On?
Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are trading higher Wednesday morning following the release of positive long-term clinical data for its lead cellular therapy.
CAPR